Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2
The first clinical efficacy results of ChAdOx1nCoV-19
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
The first clinical efficacy results of ChAdOx1nCoV-19 in a pooled analysis of phase 2/3 trials in the UK and Brazil, and safety data from more than 20 000 participants enrolled across four clinical trials in the UK, Brazil, and South Africa have been published in the Lancet.
Read more about the finding: The Lancet
We would also like to thank the Foundation Year 1 COVID-19 vaccine investigation group for their support in the COVID-19 vaccine trials:
Ali Tarfiee; Rachel Shaw; Stefan Sivapatham; Zareena Shah; Thomas Shaw; Janan Sathiendran; Eleanor Dorman; Dominic Lagrue; Lieze Thielemans; Jagruti Gohil; Charlotte Valentine; Callum Riley and Ianto Redknap.
The group contributed to the publication.
Article text (excluding photos or graphics) © Imperial College London.
Photos and graphics subject to third party copyright used with permission or © Imperial College London.